Our funds
The fund

Fondita Healthcare is an actively managed, global healthcare fund. In line with the Article 9 sustainability rating, the fund’s social sustainability objective is to invest in companies that promote health and well-being, as well as access to healthcare and equality in their own business operations.

Healthcare

The fund invests in companies that address current and unmet medical needs and provide access to medicine and medical care. This is achieved by investing in companies active in innovation, production and distribution of medicines and healthcare equipment, tools and supplies as well as diagnostics and healthcare services. Operationally, the companies are to act in a socially and environmentally responsible way.

Healthcare is an incredibly interesting, structurally growing sector and one of the three megatrends that Fondita’s thematic funds invest in.

Demographic changes with an ageing population, as well as increased welfare, translate into growing demand for healthcare. Innovation and technological advances improve care and deliver new products to fulfil current and unmet demand fueling the sector’s growth.

Sustainability
Read more about the fund’s sustainability principles:

Portfolio managers

Marcus Björkstén

Portfolio Manager, Head of Portfolio Management
Fund facts

30.6.2026

Fund size (M€)
13,1
ISIN (A)
FI4000321088
ISIN (B)
FI4000321096
Currency
EUR
Management fee
2,00 % p.a.
Risk indicator
4/7
SFDR Classification
Article 9
The fund manager's comment
Global equity markets delivered mixed performance in June. The first half of the month was characterized by geopolitical uncertainty, rising oil prices and renewed inflation concerns, which weighed on investor risk appetite. The technology sector, particularly semiconductor stocks, experienced elevated volatility as both valuations and growth expectations came under scruti...
Top holdings
Eli Lilly & Co (US)
9,8 %
Merck & Co (US)
6,4 %
AstraZeneca (SE)
5,9 %
Novo Nordisk (DK)
4,8 %
Novartis (CH)
4,7 %
USA
44 %
Switzerland
14 %
Sweden
13 %
Denmark
12 %
Belgium
7 %
Return
1 month
3,4 %
3 months
4,6 %
6 months
-4,4 %
YTD
-4,4 %
1 year
2,8 %
3 years
0,9 %
5 years
-13,7 %
since launch (14.6.2018)
39,8 %
since launch p.a.
4,3 %
Sector division
Pharma
66 %
Equipment
32 %
Cash
1 %
Top 10 holdings
Eli Lilly & Co (US)
9,8 %
Merck & Co (US)
6,4 %
AstraZeneca (SE)
5,9 %
Novo Nordisk (DK)
4,8 %
Novartis (CH)
4,7 %
Unitedhealth Group (US)
4,5 %
Danaher (US)
4,0 %
Argenx (BE)
3,7 %
Sartorius (GY)
3,5 %
Straumann (CH)
3,5 %
Country division
USA
44 %
Switzerland
14 %
Sweden
13 %
Denmark
12 %
Belgium
7 %
Germany
4 %
Other
7 %
Currency exposure
USD
44 %
EUR
16 %
CHF
14 %
SEK
13 %
DKK
12 %
GBP
2 %
Fees
TER
2,00 %
Subscription fee
0,00 %
Redemption fee
0,00 %

Total client relationship allow for changes in tariff rate.

Documents

FUND INFORMATION
KID
PAI Statements
Fund rules
Prospectus
REPORTS
Monthly report
Annual report
Semi-annual report
SUSTAINABILITY DOCUMENTS
ESG Report
Shared sustainability documents
Sustainability-related disclosures

This is marketing communication. The past performance of the investment fund does not provide any guarantee of future results. Read the fund prospectus and KID (Key Information Document) before making any investment decisions. The fund prospectus and KID are available on English, Finnish and Swedish at our website.

Our funds
Latest news
Why investing in Megatrends makes sense, especially now!

The year 2026 has been strong for our thematic strategies. Both Sustainable World and Global Megatrends have delivered meaningful risk-adjusted alpha. Fondita ... Read more

United Bankers acquires Fondita

Following the share purchase agreement signed today, United Bankers Plc has agreed to acquire a majority of the outstanding shares of Fondita ... Read more

This page was last updated

Web design: Wikström Media
Fondita online Fondita
online